Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

RenJi Hospital is the lead sponsor of 137 current clinical trials in our China register. 90 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Disitamab Vedotin, Paclitaxel and Cisplatin. The most-studied condition is Breast Cancer.

ClinicalTrials.gov trials by status

Recruiting9066%
Not yet open3223%
Active, closed129%
By invitation32%

Trials by phase

Not applicable4835%
Observational4634%
Phase 22317%
Phase 343%
Phase 143%
Phase EARLY_PHASE143%
Phase 432%
Phase 2/332%
Phase 1/221%

Clinical trials sponsored by RenJi Hospital

137 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
The Efficacy of Gallium[68Ga]NOTA-DNA Multivalent SGC8 Injection for Bladder Tumour Imaging NCT06763354 · Bladder Cancer	Not applicable	Recruiting	2025-02	China
Renal Biopsies in Post-liver Transplantation Patients With Renal Impairment NCT05326399 · Liver Transplantation, Renal Insufficiency, Chronic	Observational	Recruiting	2022-06	China
Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer NCT05910398 · Breast Cancer Invasive Drug: Pyrotinib	Phase 3	Recruiting	2023-06	China
Cohort in Qianwan New District, Ningbo NCT06387875 · ClinicalTrials.gov ↗ · Cardiovascular Diseases, Stroke, Non-Communicable Chronic Diseases	Observational	Recruiting	2023-11	China
Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial NCT07157631 · ClinicalTrials.gov ↗ · Liver Transplantation, Tranexamic Acid, End-stage Liver Disease (ESLD) Drug: Tranexamic Acid	Not applicable	Recruiting	2025-11	China
Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer NCT07396324 · ClinicalTrials.gov ↗ · HR-positive/HER2-negative Breast Cancer Drugs: Carboplatin, Iparomlimab and Tuvonralimab, Paclitaxel	Phase 2	Recruiting	2026-05	China
Target-specific immunoPET Imaging of Digestive System Carcinoma NCT06715839 · ClinicalTrials.gov ↗ · Malignancy, Digestive Cancer, Digestive System Neoplasm Drugs: [18F]F-RESCA-RB14, [18F]F-RESCA-T4, [68Ga]Ga-NOTA-T4	Not applicable	Recruiting	2024-12	China
Effectiveness and Health Economics of Endoluminal Treatment of Autologous Arteriovenous Endovascular Fistula Failure NCT06454396 · ClinicalTrials.gov ↗ · Hemodialysis Access Failure	Observational	Recruiting	2023-01	China
Evaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer NCT06478225 · ClinicalTrials.gov ↗ · Tumor Pancreas	Not applicable	Recruiting	2024-05	China
Effectiveness and Health Economics of Endoluminal Treatment of Arteriovenous Graft Fistula. NCT06470646 · ClinicalTrials.gov ↗ · Hemodialysis Access Failure	Observational	Recruiting	2023-09	China
Comparison Of Different Mechanical Thrombectomy Devices in Endovascular Treatment of Acute Iliofemoral Venous Thrombosis NCT07622212 · ClinicalTrials.gov ↗ · Deep Vein Thrombosis	Observational	Recruiting	2024-01	China
CD70-targeted immunoPET Imaging of Malignant Cancers NCT06852638 · ClinicalTrials.gov ↗ · Renal Cancer, Renal Clear Cell Carcinoma, Lymphoma	Phase 2	Recruiting	2024-12	China
Safety and Efficacy of Ventricular Irrigation for Ventriculitis NCT06358209 · ClinicalTrials.gov ↗ · Central Nervous System Infections	Not applicable	Recruiting	2025-07	China
Development and Validation of the Modified Version of VascuQol Scale in Patients With Lower Extremity Peripheral Arterial Disease. NCT06223217 · ClinicalTrials.gov ↗ · Peripheral Arterial Disease	Observational	Recruiting	2023-10	China
Multi-Dimensional MRI Spatial Heterogeneity Analysis for Predicting Key Genes and Prognosis of High-Grade Gliomas: A Multi-Center Study NCT06002711 · ClinicalTrials.gov ↗ · High-grade Glioma	Observational	Recruiting	2023-09	China
Rheolytic Thrombectomy For Acute Deep Vein Thrombosis Of Whole Lower Limb NCT05286710 · ClinicalTrials.gov ↗ · Deep Vein Thrombosis	Not applicable	Recruiting	2022-09	China
Continuous Effect Of Rehabilitation Training On Pulmonary Arterial Hypertension Patients NCT07149935 · ClinicalTrials.gov ↗ · Pulmonary Hypertension	Not applicable	Recruiting	2024-09	China
Prospective, Multicenter Clinical Study of Prolonged-release Tacrolimus in Stable Pediatric Liver Transplant Recipients NCT06183892 · ClinicalTrials.gov ↗ · Liver Transplant Drug: Tacrolimus	Not applicable	Recruiting	2024-03	China
Retrospective Analysis of Acute Pancreatitis After Percutaneous Mechanical Thrombectomy In Treatment Of Thrombotic Disorders NCT07450898 · ClinicalTrials.gov ↗ · Acute Pancreatitis (AP), Thrombotic Disorders	Observational	Recruiting	2016-01	China
Disitamab Vedotin (RC48-ADC) in Breast Cancer NCT05851677 · ClinicalTrials.gov ↗ · Breast Cancer Drug: Disitamab Vedotin	Observational	Recruiting	2023-06	China
Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE) NCT07205510 · ClinicalTrials.gov ↗ · Sarcopenia, Metabolic Diseases, All-cause Mortality	Observational	Recruiting	2020-12	China
Evaluation of the Clinical Outcomes of the Embolic Protection System in Preventing Distal Embolism During Femoropopliteal Debulking Procedures NCT07282301 · ClinicalTrials.gov ↗ · Femoropopliteal Disease	Observational	Recruiting	2025-10	China
Wearable Devices Faciliate the Management of AMI Patients NCT06995495 · ClinicalTrials.gov ↗ · Acute Myocardial Infarction	Observational	Recruiting	2024-04	China
Electroencephalography in the Management of Neuroelectric Stimulation in Patients With Severe Traumatic Brain Injuries NCT06571032 · ClinicalTrials.gov ↗ · Brain Injuries	Observational	Recruiting	2024-08	China
Biochemical Response and Clinical Outcomes in Patients With PBC NCT07449793 · ClinicalTrials.gov ↗ · Primary Biliary Cholangitis (PBC), Primary Biliary Cholangitis	Observational	Recruiting	2026-02	China
Target-specific immunoPET Imaging of Breast Cancer NCT06715826 · ClinicalTrials.gov ↗ · Breast Cancer, Breast Neoplasms, Breast Cancer Metastatic Drugs: [18F]F-RESCA-RB14, [18F]F-RESCA-RT4	Phase 1/2	Recruiting	2024-09	China
Feasibility Study of Diaphragm Synchronized Pacing (DSP) Via the Left Inferior Phrenic Vein (LIPV) Approach NCT07392749 · ClinicalTrials.gov ↗ · Heart Failure	Not applicable	Recruiting	2025-11	China
The Effects of Remimazolam on the Incidence of Severe Hypoxia During Sedated Hysteroscopy for Assisted Reproduction in Overweight or Obese Patients NCT06187896 · ClinicalTrials.gov ↗ · Hypoxia, Hysteroscopy, Overweight or Obesity Drugs: Propofol, Remimazolam	Not applicable	Recruiting	2024-01	China
Dalpiciclib in HR+/HER2- ABC NCT06301438 · ClinicalTrials.gov ↗ · Advanced Breast Cancer Drug: Dalpiciclib	Observational	Recruiting	2024-05	China
FGF19 Overexpression Combination Unified Study in HCC-19 NCT06978933 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma Drug: ABSK-011	Phase 2	Recruiting	2025-04	China
AAA-CTA Cohort Registry NCT07039825 · ClinicalTrials.gov ↗ · Abdominal Aortic Aneurysm, Image	Observational	Recruiting	2020-01	China
Effectiveness of Endoluminal Treatment of Autologous Arteriovenous Endovascular Fistula Failure NCT06493292 · ClinicalTrials.gov ↗ · Hemodialysis Access Failure	Observational	Recruiting	2024-06	China
Fractional Flow Reserve Guided Immediate Versus Staged Complete Myocardial Revascularization in Patients With ST-segment Elevation Myocardial Infarction With Multivessel Disease (Future Study) NCT05967663 · ClinicalTrials.gov ↗ · ST Elevation Myocardial Infarction	Not applicable	Recruiting	2023-11	China
Prognosis of Patients With Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy NCT06204406 · ClinicalTrials.gov ↗ · Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy	Observational	Recruiting	2023-11	China
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma NCT06091124 · ClinicalTrials.gov ↗ · Neuroendocrine Carcinoma of the Bladder, Bladder Cancer Drugs: Adebrelimab, CDDP, Cisplatin	Phase 2	Recruiting	2023-11	China
Pre-operative Therapy in Breast Cancer NCT05621564 · ClinicalTrials.gov ↗ · Breast Cancer	Observational	Recruiting	2022-11	China
COLORECTUM+ Digital System for Postoperative Quality Improvement in Colorectal Cancer NCT06685497 · ClinicalTrials.gov ↗ · Colorectal Carcinoma	Not applicable	Recruiting	2024-12	China
CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial NCT05360290 · ClinicalTrials.gov ↗ · Breast Cancer, Circulating Tumor Cell	Not applicable	Recruiting	2022-09	China
CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer NCT06306612 · ClinicalTrials.gov ↗ · Prostate Cancer	Not applicable	Recruiting	2024-03	China
CD70-targeted immunoPET Imaging of Kidney Cancer NCT06680089 · ClinicalTrials.gov ↗ · Urologic Neoplasms, Urogenital Neoplasms, Kidney Neoplasms	Phase 2	Recruiting	2024-11	China
RC48-ADC in HER2-low Advanced Breast Cancer NCT05831878 · ClinicalTrials.gov ↗ · Advanced Breast Cancer Drug: Disitamab Vedotin	Not applicable	Recruiting	2023-05	China
Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors NCT03392233 · ClinicalTrials.gov ↗ · Breast Cancer, Prostate Cancer, Non Small Cell Lung Cancer	Phase 2	Recruiting	2017-08	China
Zero Ischemia Robot-Assisted MWA Assisted Suture-less Tumor Enucleation of RCC With T1 Stage NCT06715878 · ClinicalTrials.gov ↗ · Kidney Neoplasms	Not applicable	Recruiting	2024-03	China
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma NCT05595408 · ClinicalTrials.gov ↗ · Muscle Invasive Upper Tract Urothelial Carcinoma	Observational	Recruiting	2022-02	China
Clinical Study of HIFU for Localized Prostate Cancer NCT06362577 · ClinicalTrials.gov ↗ · Localized Prostate Cancer	Observational	Recruiting	2024-05	China
Micro-encapsulated Hepatocyte Intraperitoneal Transplantation in Liver Failure Adults NCT05727722 · ClinicalTrials.gov ↗ · Acute-On-Chronic Liver Failure, Chronic Liver Failure	Phase 1	Recruiting	2024-03	China
A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis NCT07335900 · ClinicalTrials.gov ↗ · Severe Aortic Valve Stenosis	Not applicable	Recruiting	2025-12	China
Alpha-Ketoglutarate and Abdominal Aortic Aneurysm Progression and Rupture NCT04723888 · ClinicalTrials.gov ↗ · Patients With an Abdominal Aortic Aneurysm of 39-49 mm in Diameter	Not applicable	Recruiting	2021-02	China
Maximal Tumor Eradication for Oligometastatic Prostate Cancer NCT06972511 · ClinicalTrials.gov ↗ · Oligometastatic Prostate Cancer	Phase 2/3	Recruiting	2023-08	China
Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer NCT07026110 · ClinicalTrials.gov ↗ · Lung Cancer, Lung Diseases, Lung Neoplasms Drugs: [18F]F-RESCA-RT4, [18F]F-RESCA-T4, [68Ga]Ga-NOTA-RT4	Not applicable	Recruiting	2024-12	China
Comparison Of Percutaneous Mechanical Thrombectomy With Different Access in Treatment of Acute Deep Venous Thrombosis NCT06124768 · ClinicalTrials.gov ↗ · Deep Vein Thrombosis	Observational	Recruiting	2021-01	China
A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients NCT06469710 · ClinicalTrials.gov ↗ · Prostate Cancer, Circulating Tumor Cell, Leukapheresis	Observational	Recruiting	2024-06	China
Obesity Queue Database NCT06391320 · ClinicalTrials.gov ↗ · Obesity	Observational	Recruiting	2023-09	China
COVID-2019 Vaccine Immune Response Base on Single Cell Multi-Omics NCT04871932 · ClinicalTrials.gov ↗ · Immune System and Related Disorders	Observational	Recruiting	2021-02	China
Lecanemab for Early Onset Familial Alzheimer's Disease NCT06883019 · ClinicalTrials.gov ↗ · Alzheimer Disease	Observational	Recruiting	2025-03	China
A Prospective Observational Study of Perioperative Lumbar Puncture Pressure and Shunt Valve Pressure Management in Patients with Communicating Hydrocephalus Undergoing Lumboperitoneal Shunt Surgery NCT06642129 · ClinicalTrials.gov ↗ · Hydrocephalus, Communicating	Observational	Recruiting	2024-06	China
A Survey on Growth Development in Children After Liver Transplantation NCT07574398 · ClinicalTrials.gov ↗ · Growth, Development in Pediatric Liver Transplant Recipients	Observational	Recruiting	2024-11	China
Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH) NCT06458010 · ClinicalTrials.gov ↗ · Familial Hypercholesterolemia	Phase EARLY_PHASE1	Recruiting	2024-05	China
Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer NCT04254263 · ClinicalTrials.gov ↗ · Locally Advanced Breast Cancer	Phase 3	Recruiting	2019-12	China
Assessing the Prevalence and Epidemiological Characteristics of Small Intestinal Bacterial Overgrowth (SIBO) in Patients With Autoimmune Gastritis(AIG) Through Hydrogen and Methane Breath Testing(HMBT). NCT06946706 · ClinicalTrials.gov ↗ · Autoimmune Gastritis	Observational	Recruiting	2025-01	China
The Effect of Morning vs Evening Aerobic Exercise Training on Cardiac Remodeling and Function Improvement in Patients After ST Elevation Myocardial Infarction NCT06385834 · ClinicalTrials.gov ↗ · ST-segment Elevation Myocardial Infarction (STEMI)	Not applicable	Recruiting	2024-04	China
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) NCT07283692 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer Drugs: Carboplatin, Paclitaxel, Serplulimab	Phase 2	Recruiting	2026-03	China
Acostream Use in Patients With High Risk and Intermediate-risk Acute Pulmonary Embolism NCT06946732 · ClinicalTrials.gov ↗ · Pulmonary Embolism (PE)	Not applicable	Recruiting	2025-04	China
miRNA Panel for PCa Diagnosis NCT07755592 · ClinicalTrials.gov ↗ · Prostate Cancer (Diagnosis)	Observational	Recruiting	2026-04	China
GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma NCT05926726 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Not applicable	Recruiting	2023-01	China
Prospective, Observational Real-world Treatments of AEDH in Large-scale Surgical Cases NCT04229966 · ClinicalTrials.gov ↗ · Epidural Hematoma, Decompressive Craniectomy, Craniotomy	Observational	Recruiting	2020-11	China
Early ECG Prediction of Multi-system Disease Cohort Establishment and Follow Up NCT06924580 · ClinicalTrials.gov ↗ · Public Health, Public Health System Research, Multi-system Disease Diagnosis	Observational	Recruiting	2017-01	China
Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients NCT05858684 · ClinicalTrials.gov ↗ · CAR-T Cell Therapy Drug: AZD0120	Phase EARLY_PHASE1	Recruiting	2023-05	China
Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer NCT06391190 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Carcinoma, Concurrent Chemoradiotherapy, Immunotherapy	Phase 1/2	Recruiting	2022-01	China
PROfunda Femoris Vein Thrombosis Evaluation and Clearance to Improve Outcomes of Endovascular Treatment for Acute Iliofemoral Deep Vein Thrombosis NCT07622199 · ClinicalTrials.gov ↗ · Deep Vein Thrombosis	Not applicable	Recruiting	2026-06	China
Trop2-targeted immunoPET Imaging of Solid Tumors NCT06851663 · ClinicalTrials.gov ↗ · Solid Tumor, Solid Carcinoma, Uroepithelial Carcinoma Drugs: [18F]F-RESCA-RT4, [18F]F-RESCA-T4, [68Ga]Ga-NOTA-RT4	Phase 2/3	Recruiting	2024-12	China
Prospective Observational Study on Comprehensive Effects of PEEK Cranioplasty and Titanium Cranioplasty After DC（RECEPT-DC） NCT05416684 · ClinicalTrials.gov ↗ · Skull Defect	Observational	Recruiting	2024-11	China
DRug-coAted Balloon Compared With cuttinG balloON in Treatment of Arteriovenous Fistula Stenosis NCT06527963 · ClinicalTrials.gov ↗ · Arteriovenous Fistula, Angioplasty, Balloon, Hemodialysis Access Failure	Observational	Recruiting	2024-07	China
Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women NCT03201861 · ClinicalTrials.gov ↗ · Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Duct Carcinoma of Breast Drugs: Paclitaxel, Paclitaxel, Cisplatin	Phase 3	Recruiting	2017-07	China
Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma NCT06519578 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Not applicable	Recruiting	2024-08	China
Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients NCT05912816 · ClinicalTrials.gov ↗ · Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation, HER-2 ADC	Phase 2	Recruiting	2023-06	China
A Prospective Observational Study of Transcranial Doppler Ultrasound in the Assessment of Cerebral Blood Flow After Polyetheretherketone Cranioplasty NCT06642532 · ClinicalTrials.gov ↗ · Cranial Defect, TCD	Observational	Recruiting	2024-06	China
fMRI for BPS: A Descriptive Study of Findings and Symptoms NCT06294951 · ClinicalTrials.gov ↗ · Bladder Pain Syndrome	Observational	Recruiting	2024-03	China
Fibrosis Assessment in Myocardial Infarction-associated Ventricular Aneurysm NCT06994221 · ClinicalTrials.gov ↗ · Acute Myocardial Infarction, Ventricular Aneurysm Following Acute Myocardial Infarction, Myocardial Fibrosis	Observational	Recruiting	2024-11	China
CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer NCT05795335 · ClinicalTrials.gov ↗ · Breast Cancer	Observational	Recruiting	2023-04	China
ImmunoPET Imaging of Pancreatic Cancer NCT06602037 · ClinicalTrials.gov ↗ · Neoplasms Pancreatic	Not applicable	Recruiting	2024-11	China
Swartz Sheath With Angioplasty Guidewire-Assisted Technique for Patent Foramen Ovale Closure (STAGE-PFO) NCT06793969 · ClinicalTrials.gov ↗ · Patent Oval Foramen	Not applicable	Recruiting	2023-12	China
Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1) NCT06511349 · ClinicalTrials.gov ↗ · Type 1 Primary Hyperoxaluria Drug: YOLT-203	Phase EARLY_PHASE1	Recruiting	2024-07	China
Prophylactic Tranexamic Acid Reduces Postpartum Hemorrhage NCT06754371 · ClinicalTrials.gov ↗ · Postpartum Hemorrhage, Systemic Autoimmune Diseases Drug: Tranexamic Acid	Phase 4	Recruiting	2025-01	China
The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure NCT06081647 · ClinicalTrials.gov ↗ · Hypoxia, Gastric Polyp, Colon Cancer	Not applicable	Recruiting	2023-12	China
DEB-TACE Prior to Liver Transplantation in the Treatment of HCC NCT06353126 · ClinicalTrials.gov ↗ · Liver Cancer	Phase 4	Recruiting	2024-10	China
Smart Flex Stent System for the Treatment Long Femoropopliteal Artery Lesions NCT05894863 · ClinicalTrials.gov ↗ · Peripheral Arterial Disease	Not applicable	Recruiting	2023-05	China
Study on the Safety and Efficacy of Sodium Phosphate Powder for Intestinal Preparation in People Aged 50 to 70 Years Old NCT06652906 · ClinicalTrials.gov ↗ · Physical Examination	Phase 2	Recruiting	2024-06	China
Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients NCT06394063 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus Drug: Telitacicept	Not applicable	Recruiting	2024-06	China
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy NCT06249438 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE), Immune-mediated Necrotizing Myopathy (IMNM), Neuromyelitis Optica Spectrum Disorders (NMOSD)	Phase 1	Recruiting	2024-03	China
Ciprofol vs Propofol for Hemodynamic Stability in Patients Having General Anesthesia for Endovascular Thrombectomy After Ischemic Stroke NCT07696208 · Hemodynamic Stability, Ischemic Strokes Drugs: Ciprofol, Propofol	Phase 4	Not yet open	2026-07	China
JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases NCT06567080 · ClinicalTrials.gov ↗ · B-cell Tumors, Autoimmune Diseases, Lupus Erythematosus, Systemic	Phase 1	Not yet open	2024-09	China
Atherectomy Followed With a Drug Coated Balloon in the Treatment of Long Femoropopliteal Lesions NCT05868564 · ClinicalTrials.gov ↗ · Peripheral Arterial Disease	Not applicable	Not yet open	2023-07	China
Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma NCT07584733 · ClinicalTrials.gov ↗ · Upper Tract Urothelial Carcinoma Drugs: Disitamab Vedotin, Tislelizumab	Phase 2	Not yet open	2026-05	China
OXiris for Abdominal SEptic Shock (OASES Study) NCT06504316 · ClinicalTrials.gov ↗ · Septic Shock, Abdominal Sepsis, Multi Organ Failure	Not applicable	Not yet open	2024-08	China
EEG-TMS Intervening Against Postoperative Delirium NCT07100197 · ClinicalTrials.gov ↗ · Postoperative Delirium	Not applicable	Not yet open	2025-07	China
REST4-AAA Registry NCT07056491 · ClinicalTrials.gov ↗ · Abdominal Aortic Aneurysm	Observational	Not yet open	2025-07	China
Dual GIP/GLP-1 Receptor Agonist in Obese Women Before Frozen Embryo Transfer NCT07811895 · ClinicalTrials.gov ↗ · Tirzepatide, Frozen Embryo Transfer, Obesity	Not applicable	Not yet open	2026-09	China
The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching NCT07678645 · ClinicalTrials.gov ↗ · Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Atopic Dermatitis (AD) Drug: Upadacitinib	Phase 2	Not yet open	2026-06	China
An Exploratory Study of Iliac Artery Branch Stent for Internal Iliac Artery Reconstruction in Abdominal Aortic Aneurysm/Iliac Aneurysm Repair NCT06162273 · ClinicalTrials.gov ↗ · Aortic Aneurysm, Abdominal, Iliac Aneurysm	Observational	Not yet open	2023-12	China

Showing the 100 most recently updated of 137 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in RenJi Hospital trials

44 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 4 more in the trial list above.

Conditions in RenJi Hospital trials

200 conditions

Breast Cancer8 Peripheral Arterial Disease4Hemodialysis Access Failure4Deep Vein Thrombosis4Bladder Cancer3Decompressive Craniectomy3Prostate Cancer3 Hepatocellular Carcinoma3Liver Transplantation2Renal Insufficiency, Chronic2 Cardiovascular Diseases2Non-Communicable Chronic Diseases2Acute Myocardial Infarction2Primary Biliary Cholangitis (PBC)2Abdominal Aortic Aneurysm2Obesity2 Hypoxia2 Advanced Breast Cancer2Epidural Hematoma2Craniotomy2Tubular Breast Cancer2Mucinous Breast Cancer2Circulating Tumor Cell2Kidney Neoplasms2

By trial register

Register	Trials	Recruiting
Clinical trials in China	137	90

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Breast Cancer

Sponsor	Trials
Fudan University	48
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	21
Second Affiliated Hospital, Zhejiang University, School of Medicine	19
AstraZeneca	15
Shengjing Hospital	15
Pfizer	12
Sichuan Baili Pharmaceutical	12
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	12
Hoffmann-La Roche	10
Ruijin Hospital	10

Sponsors with the most current trials registered for this condition.

Questions about RenJi Hospital trials

How many clinical trials does RenJi Hospital sponsor?

RenJi Hospital is the lead sponsor of 137 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are RenJi Hospital trials recruiting?

Yes. 90 of its 137 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is RenJi Hospital testing?

Its current trials name 44 drugs and biologicals as interventions. The most frequent are Disitamab Vedotin (5), Paclitaxel (5), Cisplatin (4), [18F]F-RESCA-RT4 (3) and [18F]F-RESCA-T4 (3). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

RenJi Hospital clinical trials